At a glance
| Full name | Delta sleep-inducing peptide |
|---|---|
| Molecular size | Nine amino acids |
| Main historical use | Experimental sleep research |
| Controlled evidence | Small and inconsistent |
| Clinical boundary | No established U.S. insomnia indication |
Overview
DSIP entered research through experiments on sleep-related activity and subsequently appeared in human studies of insomnia, pain, and withdrawal syndromes. These are separate indications and should not be pooled into a single claim of broad therapeutic usefulness. Much of the clinical literature is small and several decades old. It includes both favorable pilot reports and controlled studies with limited benefit. The existence of an identifiable peptide and an evocative name can make the evidence sound more settled than it is. A modern assessment must ask whether objective sleep, subjective sleep quality, daytime functioning, and longer-term safety all improved meaningfully.
How it works
DSIP has been investigated in relation to sleep regulation, stress responses, and interactions with neurochemical systems. A clinically validated, selective receptor mechanism that predicts reliable insomnia benefit has not been established in the cited human studies. Changes in sleep-stage measurements are informative physiological observations, but they must be connected to how people sleep and function before they can support a treatment claim.
What controlled insomnia studies found
A double-blind study of 16 people with chronic insomnia found some objective differences but concluded that the effects were weak and unlikely to offer major therapeutic benefit. Subjective sleep quality did not improve. A separate crossover study likewise judged observed sleep improvement to have little clinical significance. These findings temper positive claims from earlier pilot work.
Why other pilot studies do not settle the issue
An uncontrolled chronic-pain pilot involved seven people with heterogeneous symptoms. Comparing patients with their own earlier state cannot adequately exclude natural variation or expectation. Evidence from pain or withdrawal studies also cannot be transferred directly to insomnia, where meaningful endpoints and competing explanations differ.
Supporting sources [3]
What remains unknown
Small, short historical studies cannot reliably detect uncommon adverse effects or define long-term use and interactions. FDA identifies route-specific safety-information gaps and potential immunogenicity concerns for compounded emideltide, another name for DSIP. These uncertainties do not erase the old human studies, but they prevent assuming that current commercial preparations have an established safety profile.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Experimental nonapeptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DSIP in chronic insomnia: double-blind study of 16 patients ↗Clinical trial source · Checked 2026-10-27
- Short-term DSIP in chronic insomnia: double-blind crossover study ↗Clinical trial source · Checked 2026-10-27
- DSIP for chronic pain episodes: seven-patient pilot study ↗Clinical trial source · Checked 2026-10-27
- FDA: safety concerns for certain bulk substances proposed for compounding ↗Regulatory source · Checked 2026-10-27